Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients

Abstract

Background

Enthesitis is a hallmark of psoriatic arthritis (PsA) and echographic ultrasounds (US) represent a support for diagnosis of pre-clinical signs of enthesitis in asymptomatic patients at high risk for advanced forms. Early treatment with anti-TNFα could prevent permanent damage contrasting the degenerative course of the disease.

Objectives

To evaluate the effects of adalimumab on echographic and preclinical enthesitis signs in patients affected by plaque psoriasis.

Methods

49 psoriatic patients undergoing adalimumab treatment for plaque-type psoriasis were subjected to echographic screening for identifying pre-clinical signs of enthesitis. Patients underwent clinical and ultrasonographic examination of hands, elbows and knees before starting adalimumab and after 24 and 48 weeks of treatment.

Results

We observed a reduction of the total number of echographic abnormalities and a significant decrease of the thickness of quadriceps tendons at week 24 and week 48. Furthermore, there was no evidence of significant articular damage progression during the entire study duration.

Conclusions

Entheseal ultrasonography may be used for preclinical diagnosis of PsA.

Our study demonstrates that early detection and management with adalimumab leads to a block of articular damage progression. On quadriceps tendon, adalimumab has shown to be effective with a significant thickening reduction at week 24 and 48

Keywords:

• Biologics
• psoriatic arthritis
• enthesitis

Disclosure statement

AN has served on advisory boards, received honoraria for lectures and research grants from Almirall, Abbvie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi-Genzyme, Amgen and Boehringer Ingelheim. MV has no conflicts of interest to declare. C. DS served as an advisory board member and consultant and has received speaker’s honoraria from Abbvie, MSD, Allmiral, Pfizer, Leo Pharma, Lilly, Novartis, UCB-Pharma, Sanofi, Janssen, and Celgene. ME has been a scientific consultant/speaker for Abbvie, Novartis, Eli-Lilly, Biogen, LEO-Pharma. AC has served on advisory boards Celgene, UCB, Eli Lilly, Pfizer, Janssen, Novartis, Sanofi-Genzyme and MSD. AR, MT e GA have no conflicts of interest to declare.